expert
committe
produc
institut
medicin
report
emerg
infect
defin
new
reemerg
drugresist
infect
whose
incid
human
increas
within
past
two
decad
whose
incid
threaten
increas
near
futur
addit
six
major
contributor
diseas
present
includ
chang
human
demograph
behavior
advanc
technolog
chang
industri
practic
econom
develop
chang
landus
pattern
dramat
increas
volum
speed
intern
travel
commerc
microbi
adapt
chang
breakdown
public
health
capac
common
theme
recent
emerg
infecti
diseas
major
anim
origin
fact
vectorborn
pathogen
project
introduc
new
region
includ
rift
valley
fever
japanes
enceph
virus
america
crimeancongo
hemorrhag
fever
viru
eurasia
addit
major
viral
addit
cost
human
life
emerg
reemerg
infecti
diseas
costli
financi
recent
zika
outbreak
estim
cost
billion
econom
loss
world
health
organ
priorit
number
infecti
diseas
requir
urgent
need
research
develop
given
concern
potenti
sever
outbreak
articl
review
major
emerg
infect
list
other
emerg
usa
well
recent
emerg
priorit
high
likelihood
caus
outbreak
futur
outbreak
southern
china
atyp
pneumonia
undetermin
etiolog
spread
neighbor
countri
eventu
across
world
coronaviru
caus
sever
acut
respiratori
syndrom
sar
discov
hong
kong
beij
sever
affect
citi
estim
cost
far
east
approxim
billion
may
alon
probabl
case
report
countri
mortal
rate
end
epidem
juli
sar
reemerg
small
scale
end
positivesens
rna
coronaviru
whose
mean
incub
period
day
clinic
present
vari
patient
age
children
develop
typic
mild
upper
respiratori
tract
infect
teenag
adult
develop
sever
predict
cours
phase
cours
associ
increas
viral
load
flulik
symptom
phase
ii
character
recurr
fever
hypoxemia
progress
pneumonia
would
requir
supplementari
oxygen
approxim
would
requir
intub
due
develop
acut
respiratori
distress
syndrom
ard
wateri
diarrhea
promin
extrapulmonari
manifest
addit
hepat
common
complic
patient
occasion
develop
neurolog
manifest
includ
statu
epilepticu
clinic
worsen
phase
ii
thought
immunemedi
laboratori
find
includ
lymphopenia
elev
aminotransferas
elev
lactat
dehydrogenas
ldh
creatin
kinas
ck
result
consist
dissemin
intravascular
coagulopathi
progress
unilater
opac
bilater
involv
found
imag
sar
detect
respiratori
secret
urin
fece
howev
notabl
find
diffus
alveolar
damag
advanc
age
sever
hepat
high
initi
ldh
high
neutrophilia
present
diabet
mellitu
low
count
high
initi
viral
load
prognost
factor
sever
diseas
survivor
shown
persist
lung
function
abnorm
spread
close
contact
via
droplet
transmiss
though
evid
might
follow
airborn
transmiss
viru
high
rate
infect
healthcar
worker
account
approxim
case
origin
outbreak
thought
start
handl
wild
anim
particularli
civet
cat
raccoon
dog
suspect
patient
place
respiratori
isol
singl
test
result
either
posit
neg
insuffici
make
conclus
patient
diagnosi
fals
posit
fals
neg
occur
initi
test
via
serolog
reversetranscriptasepolymeras
chain
reaction
rtpcr
howev
two
specimen
obtain
either
differ
sourc
sourc
differ
occas
confirm
diagnosi
specimen
obtain
nasopharyng
swab
stool
addit
seroconvers
anoth
diagnost
method
vital
identifi
patient
sar
isol
within
day
ill
significantli
reduc
secondari
transmiss
although
ribavirin
use
initi
outbreak
shown
vitro
activ
viru
corticosteroid
use
latephas
rescu
purpos
may
prolong
viremia
given
earli
agent
shown
promis
includ
monoclon
antibodi
nitric
oxid
proteas
inhibitor
interferon
yet
shown
activ
human
anim
studi
part
concern
potenti
futur
epidem
lie
fact
famili
virus
sar
come
notori
frequent
mutat
addit
decreas
worldwid
attent
lead
decreas
fund
research
report
case
sar
sinc
middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
coronaviru
envelop
positivesens
rna
genom
clinic
featur
may
includ
flulik
symptom
gastrointestin
symptom
sever
pneumonia
acut
respiratori
distress
syndrom
septic
shock
dissemin
intravascular
coagulopathi
multiorgan
failur
lab
find
may
includ
lymphopenia
thrombocytopenia
elev
ldh
level
elev
aminotransferas
howev
approxim
case
mild
symptom
almost
sever
symptom
incub
period
day
children
younger
adult
seem
less
suscept
larg
proport
confirm
pediatr
case
asymptomat
acquir
via
household
contact
primari
infect
result
contact
dromedari
camel
product
though
humantohuman
transmiss
possibl
case
acquir
via
human
transmiss
tend
mild
number
infect
contact
tend
limit
fact
major
secondari
case
associ
healthcar
set
major
outbreak
occur
case
healthcar
worker
except
south
korea
outbreak
limit
middl
east
dromedari
camel
found
south
korean
outbreak
case
death
case
import
europ
asia
africa
usa
tabl
case
usa
detect
promptli
secondari
case
occur
case
occur
may
healthcar
worker
saudi
arabia
juli
laboratoryconfirm
case
major
saudi
arabia
reproduct
number
less
signific
heterogen
south
korean
outbreak
spreader
significantli
higher
rate
underli
pulmonari
diseas
transmiss
occur
earli
diseas
cours
day
symptom
onset
associ
patient
go
multipl
healthcar
facil
diagnosi
humantohuman
transmiss
seem
requir
close
contact
though
sustain
case
requir
hospit
chronic
comorbid
obes
diabet
endstag
renal
diseas
chronic
lung
diseas
mortal
rate
among
critic
ill
patient
frequent
underli
chronic
diseas
extrapulmonari
manifest
common
mer
detect
respiratori
tract
secret
bronchoalveolar
lavag
specimen
provid
better
yield
nasopharyng
swab
howev
serum
sampl
may
also
obtain
center
diseas
control
prevent
cdc
recommend
evalu
patient
respiratori
symptom
travel
affect
countri
within
day
cluster
patient
sever
acut
respiratori
diseas
merscov
evalu
test
perform
h
exposur
healthcar
worker
exposur
aerosolgener
procedur
high
risk
transmiss
cdc
recommend
airborn
contact
precaut
suspect
known
case
patient
suspect
mer
admit
short
breath
pneumonia
hypoxemia
otherwis
may
care
home
isol
howev
case
care
select
potenti
spread
treatment
primarili
support
mechan
ventil
renal
replac
therapi
need
specif
antivir
develop
number
studi
perform
varieti
medic
includ
interferon
ifn
ribavirin
proteas
inhibitor
mycophenol
acid
cyclosporin
chloroquin
nitazoxanid
antibiot
fusion
inhibitor
steroid
perhap
promis
human
studi
involv
combin
ribavirin
interferon
though
overal
result
mix
shown
benefit
critiqu
treatment
late
studi
shown
improv
surviv
day
other
shown
improv
surviv
small
retrospect
studi
eight
patient
receiv
combin
therapi
mycophenol
acid
surviv
though
lower
acut
physiolog
chronic
health
evalu
ii
score
compar
patient
receiv
agent
two
new
virus
recent
discov
usa
heartland
bourbon
virus
heartland
viru
member
bunyavirida
famili
genu
phleboviru
singlestrand
negativesens
rna
lone
star
tick
amblyomma
americanum
transmit
diseas
first
discov
farmer
missouri
clinic
featur
includ
flulik
symptom
leukopenia
thrombocytopenia
mild
transamin
develop
within
day
tick
bite
six
addit
case
identifi
four
patient
hospit
one
patient
multipl
underli
diseas
die
five
patient
missouri
one
tennesse
deceas
patient
develop
hypoxem
respiratori
failur
sever
thrombocytopenia
acut
kidney
injuri
upper
gastrointestin
bleed
famili
ultim
opt
transit
comfort
measur
clinic
cours
consist
sever
infect
ehrlichia
chaffeensi
except
improv
doxycyclin
diagnosi
suspect
patient
improv
doxycyclin
therapi
made
detect
viral
rna
rtpcr
bourbon
viru
genu
thogotoviru
within
famili
orthomyxovirida
pleomorph
rna
genom
case
patient
bourbon
counti
kansa
within
sever
day
tick
bite
develop
flulik
symptom
later
find
includ
leukopenia
thrombocytopenia
hyponatremia
mild
transamin
case
patient
develop
congest
heart
failur
later
die
withdraw
care
studi
tick
popul
missouri
reveal
amblyomma
americanum
tick
carrier
viru
though
transmiss
tick
certain
littl
known
otherwis
diseas
confirm
case
scarc
anoth
emerg
infecti
diseas
dimorph
fungu
emergomyc
canadensi
although
emergomyc
speci
discov
throughout
europ
africa
e
canadensi
recent
discov
north
america
emergomyc
previous
name
emmonsialik
pathogen
numer
speci
emergomyc
common
e
africanu
caus
infect
hiv
south
africa
anim
infect
document
four
case
note
far
immunocompromis
patient
develop
system
diseas
fungemia
patient
commonli
pneumonia
well
skin
lesion
suspect
inhal
infect
occur
geograph
rang
involv
central
western
north
america
diagnosi
made
via
histopatholog
cultur
affect
tissu
limit
suscept
test
shown
suscept
itraconazol
amphotericin
b
treatment
follow
typic
guidelin
dimorph
fungal
infect
immunocompromis
host
amphotericin
b
week
follow
itraconazol
month
one
concern
emerg
infecti
diseas
new
delhi
enterobacteriacea
superbug
seem
origin
indian
subcontin
case
first
report
though
retrospect
analysi
show
presenc
earli
gene
carri
plasmid
easili
spread
among
bacteria
although
carbapenamas
new
level
promiscu
higher
other
addit
studi
shown
high
level
interlineag
interspeci
gene
transfer
though
domin
mechan
seem
latter
commonli
found
among
escherichia
coli
klebsiella
pneumonia
also
found
within
speci
enterobacteriacea
well
acinetobact
baumanii
pseudomona
speci
although
gramneg
bacteria
typic
treat
fluoroquinolon
aminoglycosid
ndmposit
pathogen
contain
antibiot
resist
gene
suscept
tigecyclin
colistin
except
strain
sensit
aztreonam
certain
aminoglycosid
multipl
variant
report
ie
wide
found
throughout
hospit
strain
well
commun
strain
india
consist
rate
extendedspectrum
esbl
commun
hospit
set
like
overus
antibiot
led
excret
wast
water
system
ultim
result
selectionpressur
multidrugresist
organ
fact
estim
least
million
indian
resid
gut
flora
consist
bacteria
spread
numer
countri
believ
medic
tourism
industri
propag
dissemin
fact
seven
eight
tourist
india
colon
esblposit
bacteria
upon
return
upon
departur
balkan
anoth
area
high
rate
ndmposit
bacteria
spread
contin
except
south
america
antarctica
fig
refer
ndmposit
bacteria
even
found
companion
anim
usa
ad
concern
antimicrobi
research
pipelin
activ
gramneg
pathogen
rift
valley
fever
viru
rvfv
singlestrand
rna
viru
genu
phleboviru
famili
bunyavirida
major
infect
individu
asymptomat
patient
symptomat
selflimit
febril
ill
howev
small
minor
develop
sever
diseas
acut
hepat
renal
failur
hemorrhag
manifest
surviv
phase
often
develop
neurolog
symptom
consist
vision
loss
enceph
longterm
sequela
may
develop
blind
hemiparesi
quadriparesi
incontin
hallucin
coma
fatal
rate
though
patient
hemorrhag
diseas
fatal
rate
high
diagnosi
made
detect
viral
rna
immunoglobulin
serolog
particularli
acut
febril
stage
often
transmit
mosquito
typic
aed
genu
though
exposur
infect
anim
tissu
consumpt
product
also
caus
diseas
rvfv
endem
subsaharan
africa
period
outbreak
heavi
rainfal
flood
spread
middl
east
french
island
mayott
outbreak
often
signific
effect
human
livestock
characterist
rvfv
outbreak
includ
sudden
increas
abort
mortal
young
anim
appear
diseas
human
model
develop
success
predict
outbreak
use
satellit
imageri
sea
surfac
temperatur
rainfal
veget
given
spread
africa
concern
reach
mediterranean
basin
europ
number
compet
vector
rvfv
identifi
europ
addit
isol
hematophag
arthropod
includ
tick
sand
fli
though
signific
current
understood
current
specif
treatment
though
vaccin
provid
protect
follow
primari
inocul
singl
boost
schedul
crimeancongo
hemorrhag
fever
viru
cchfv
produc
first
major
known
outbreak
crimean
peninsula
though
like
caus
outbreak
centuri
identifi
recent
emerg
list
prioriti
agent
research
develop
due
potenti
spread
caus
sever
outbreak
cchfv
member
bunyavirida
famili
genu
nairoviru
mani
alias
includ
asian
ebola
karakhalak
black
death
khunymuni
nose
bleed
khungribta
blood
take
cchfv
deriv
name
outbreak
crimea
belgian
congo
report
throughout
mani
part
africa
middl
east
europ
asia
fig
refer
crimeancongo
hemorrhag
fever
cchf
widespread
tickborn
viral
infect
human
negativesens
rna
viru
transmit
numer
tick
speci
agricultur
worker
commonli
affect
addit
humantohuman
transmiss
may
occur
via
contact
skin
mucou
membran
bodi
fluid
infect
patient
standard
barrier
precaut
recommend
patient
suspect
diseas
domest
livestock
main
reservoir
outbreak
increas
recent
year
like
target
viru
endotheli
cell
hepat
cell
kupffer
cell
clinic
cours
cchf
follow
phase
consist
incub
prehemorrhag
hemorrhag
convalesc
spectrum
sever
mild
febril
ill
hemorrhag
shock
multiorgan
failur
incub
period
vari
method
acquisit
typic
take
day
tick
bite
day
exposur
infect
patient
prehemorrhag
stage
nonspecif
flulik
symptom
hemorrhag
stage
follow
develop
within
day
symptom
sever
diseas
one
differenti
featur
sever
ill
patient
often
develop
pattern
larg
ecchymosi
seen
hemorrhag
fever
laboratori
find
includ
leukopenia
thrombocytopenia
elev
aminotransferas
elev
ck
ldh
prolong
prothrombin
time
activ
partial
thromboplastin
time
convalesc
usual
occur
day
onset
ill
diagnosi
commonli
made
via
detect
viral
rna
rtpcr
serolog
tradit
specif
treatment
cchf
though
ribavirin
demonstr
vitro
vivo
activ
furthermor
cdc
recommend
use
ribavirin
report
turkey
claim
combin
methylprednisolon
intraven
immunoglobulin
ivig
freshfrozen
plasma
benefici
control
group
comparison
ivig
methylprednisolon
may
benefici
improv
thrombocytopenia
two
vaccin
develop
though
random
clinic
trial
cchf
never
demonstr
vaccin
individu
bulgarian
ministri
health
report
fourfold
decreas
case
sinc
vaccin
implement
ribavirin
might
benefici
postexposur
prophylaxi
mortal
rate
vari
worsen
prognosi
diseas
acquir
nosocomi
higher
level
aminotransferas
higher
viremia
coagulopathi
longterm
sequela
document
rare
perman
includ
impair
vision
neurolog
symptom
cchf
epidem
potenti
high
rate
mortal
nosocomi
infect
difficulti
prevent
treatment
addit
genet
divers
arbovirus
attempt
control
cchf
via
erad
tick
vector
proven
ineffici
domest
anim
asymptomat
even
highli
virem
infecti
diseas
promis
one
biggest
challeng
come
decad
new
one
emerg
unpredict
success
clinic
outcom
requir
proactiv
approach
research
develop
human
behavior
contribut
new
infect
emerg
particularli
zoonos
although
strategi
would
prove
costli
articl
demonstr
exampl
much
emerg
infecti
diseas
cost
outbreak
articl
review
number
emerg
infect
categor
prioriti
research
develop
due
potenti
epidem
even
pandem
addit
review
concern
drugresist
mechan
threaten
provid
bacteria
resist
antibiot
final
infecti
diseas
emerg
usa
cover
though
littl
known
pauciti
case
date
